Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 98 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alcoholic Cirrhosis Clear all
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
165
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 3 Interventional

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
126
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

NCT02083367
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 23, 2026, 8:19 PM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

NCT03838250
View directory record Official record
Conditions
Alcoholic Liver Cirrhosis
Interventions
Cellgram™ (Bone marrow-derived MSCs)
Biological
Lead sponsor
Pharmicell Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

NCT01937130
View directory record Official record
Conditions
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

NCT05039450
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EFX, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
46
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

NCT03486899
View directory record Official record
Conditions
Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
83
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Pegfilgrastim in Patients With Alcoholic Hepatitis

NCT02776059
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Standard of care + pegfiltrastim, Standard of care
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Loma Linda, California • Long Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

SAMe Trial for Patients With Alcoholic Cirrhosis

NCT04250259
View directory record Official record
Conditions
Alcoholic Cirrhosis
Interventions
Placebo, SAMe 400 mg tablet
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated No phase listed Observational

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125
View directory record Official record
Conditions
Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 1 Interventional

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT07553663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Weight Management in Nonalcoholic Steatohepatitis

NCT00266019
View directory record Official record
Conditions
Fatty Liver
Interventions
Weight Management (diet, exercise, and behavior modification)
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

NCT04267393
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
BMS-986263, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

NCT04175392
View directory record Official record
Conditions
Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
Interventions
Align Probiotic Supplement Capsule, Placebos
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Sep 23, 2026, 8:19 PM EDT